Sigilon Therapeutics, Inc. – NASDAQ:SGTX
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Sigilon Therapeutics stock price monthly change
+369.11%
month
Sigilon Therapeutics stock price quarterly change
+4466.15%
quarter
Sigilon Therapeutics stock price yearly change
+2942.65%
year
Sigilon Therapeutics key metrics
Market Cap | 56.21M |
Enterprise value | 8.72M |
P/E | -0.67 |
EV/Sales | 0.67 |
EV/EBITDA | -0.21 |
Price/Sales | 1.75 |
Price/Book | 0.58 |
PEG ratio | -0.01 |
EPS | -3.67 |
Revenue | 17.65M |
EBITDA | -26.84M |
Income | -29.57M |
Revenue Q/Q | 104.64% |
Revenue Y/Y | 76.80% |
Profit margin | -336.53% |
Oper. margin | -337.35% |
Gross margin | 22.27% |
EBIT margin | -337.35% |
EBITDA margin | -152.07% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSigilon Therapeutics stock price history
Sigilon Therapeutics stock forecast
Sigilon Therapeutics financial statements
| Sep 2022 | 4.25M | -8.91M | -209.76% |
|---|---|---|---|
| Dec 2022 | 2.64M | -5.64M | -213.31% |
| Mar 2023 | 4.85M | -7.50M | -154.57% |
| Jun 2023 | 5.9M | -7.50M | -127.22% |
| 2023-08-07 | -4.71 | -2.89 |
|---|
| Sep 2022 | 94618000 | 50.20M | 53.06% |
|---|---|---|---|
| Dec 2022 | 87278000 | 48.13M | 55.15% |
| Mar 2023 | 76588000 | 43.29M | 56.53% |
| Jun 2023 | 55559000 | 28.11M | 50.6% |
| Sep 2022 | -9.98M | 8.26M | 13K |
|---|---|---|---|
| Dec 2022 | -7.21M | 18.02M | -1.66M |
| Mar 2023 | -11.40M | 12.23M | -1.64M |
| Jun 2023 | -4.15M | -108K | -17.36M |
Sigilon Therapeutics alternative data
| Aug 2023 | 62 |
|---|---|
| Sep 2023 | 62 |
| Oct 2023 | 62 |
| Nov 2023 | 62 |
| Dec 2023 | 62 |
| Jan 2024 | 62 |
| Feb 2024 | 62 |
| Mar 2024 | 62 |
| Apr 2024 | 62 |
| May 2024 | 62 |
| Jun 2024 | 62 |
| Jul 2024 | 62 |
Sigilon Therapeutics other data
16.91%
-37.10%
of SGTX is owned by hedge funds
5.47M
-12.02M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 1718493 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ELI LILLY & CO 10 percent owner | Common Stock | 1,718,493 | $14.92 | $25,639,916 | ||
Option | YUAN QING SARAH officer: CTOO | Stock Option (Right to Buy) | 2,884 | $19.24 | $55,488 | ||
Option | YUAN QING SARAH officer: CTOO | Common Stock | 2,884 | $19.24 | $55,488 | ||
Option | PONTES JOSIAS officer: CHIEF FINANCIAL OFFICER | Common Stock | 1,444 | $19.24 | $27,783 | ||
Option | PONTES JOSIAS officer: CHIEF FINANCIAL OFFICER | Stock Option (Right to Buy) | 1,444 | $19.24 | $27,783 | ||
Option | VIVALDI COELHO ROGERIO director, officer.. | Stock Option (Right to Buy) | 5,528 | $19.24 | $106,359 | ||
Option | VIVALDI COELHO ROGERIO director, officer.. | Common Stock | 5,528 | $19.24 | $106,359 | ||
Sale | RUFFOLO ROBERT R | Common Stock | 6,750 | N/A | N/A | ||
Option | RUFFOLO ROBERT R | Stock Option (Right to Buy) | 6,750 | N/A | N/A | ||
Option | RUFFOLO ROBERT R | Common Stock | 6,750 | N/A | N/A |
| Patent |
|---|
Application Filling date: 27 Mar 2020 Issue date: 25 Aug 2022 |
Application Filling date: 27 Sep 2019 Issue date: 6 Jan 2022 |
Application Filling date: 27 Mar 2019 Issue date: 20 May 2021 |
Application Filling date: 27 Mar 2019 Issue date: 20 May 2021 |
Application Filling date: 1 Mar 2019 Issue date: 4 Mar 2021 |
Application Filling date: 1 Mar 2019 Issue date: 7 Jan 2021 |
Application Filling date: 27 Sep 2018 Issue date: 20 Aug 2020 |
Application Filling date: 3 Oct 2017 Issue date: 6 Feb 2020 |
-
When is Sigilon Therapeutics's next earnings date?
Unfortunately, Sigilon Therapeutics's (SGTX) next earnings date is currently unknown.
-
Does Sigilon Therapeutics pay dividends?
No, Sigilon Therapeutics does not pay dividends.
-
How much money does Sigilon Therapeutics make?
Sigilon Therapeutics has a market capitalization of 56.21M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 34.85% to 12.94M US dollars. Sigilon Therapeutics made a loss 43.46M US dollars in net income (profit) last year or -$2.89 on an earnings per share basis.
-
What is Sigilon Therapeutics's stock symbol?
Sigilon Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SGTX".
-
What is Sigilon Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sigilon Therapeutics?
Shares of Sigilon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sigilon Therapeutics's key executives?
Sigilon Therapeutics's management team includes the following people:
- Dr. Rogerio Vivaldi Coelho M.D., MBA Pres, Chief Executive Officer & Director(age: 61, pay: $802,370)
- Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD Co-Founder & Member of Scientific Advisory Board(age: 76, pay: $101,890)
- Dr. Daniel G. Anderson Ph.D. Co-Founder & Member of Scientific Advisory Board(age: 55, pay: $100,630)
-
Is Sigilon Therapeutics founder-led company?
Yes, Sigilon Therapeutics is a company led by its founders Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD and Dr. Daniel G. Anderson Ph.D..
-
How many employees does Sigilon Therapeutics have?
As Jul 2024, Sigilon Therapeutics employs 62 workers.
-
When Sigilon Therapeutics went public?
Sigilon Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 4 Dec 2020.
-
What is Sigilon Therapeutics's official website?
The official website for Sigilon Therapeutics is sigilon.com.
-
Where are Sigilon Therapeutics's headquarters?
Sigilon Therapeutics is headquartered at 100 Binney Street, Cambridge, MA.
-
How can i contact Sigilon Therapeutics?
Sigilon Therapeutics's mailing address is 100 Binney Street, Cambridge, MA and company can be reached via phone at +61 73367540.
Sigilon Therapeutics company profile:
Sigilon Therapeutics, Inc.
sigilon.comExchange:
NASDAQ
Full time employees:
62
Industry:
Biotechnology
Sector:
Healthcare
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
100 Binney Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001821323
ISIN: US82657L1070
CUSIP: 82657L107
